Get the Stockscreener App
2.39
7.00%
-0.18
After Hours:
2.46
0.07
+2.93%
Windtree Therapeutics Inc stock is traded at $2.39, with a volume of 589.80K.
It is down -7.00% in the last 24 hours and down -70.53% over the past month.
Windtree Therapeutics Inc is a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases. Its portfolio of product candidates includes istaroxime, a Phase 2 candidate with sarco endoplasmic reticulum Ca2+ -ATPase 2a, or SERCA2a, activating properties for acute heart failure and associated cardiogenic shock, preclinical SERCA2a activators for heart failure, rostafuroxin for the treatment of hypertension in patients with a specific genetic profile, and a preclinical atypical protein kinase C iota, or aPKCi, inhibitor, being developed for potential application in rare and broad oncology indications. It operates in one operating segment, which is the research and development of products focused on cardiovascular disease.
See More
Previous Close:
$2.57
Open:
$2.53
24h Volume:
589.80K
Relative Volume:
0.45
Market Cap:
$3.87M
Revenue:
-
Net Income/Loss:
$-24.83M
P/E Ratio:
-0.0922
EPS:
-25.91
Net Cash Flow:
$-13.27M
1W Performance:
-30.32%
1M Performance:
-70.53%
6M Performance:
+575.14%
1Y Performance:
+151.95%
1-Day Range:
$2.3392
$2.5708
1-Week Range:
$2.3392
$3.3599
52-Week Range:
$0.2654
$14.75
Windtree Therapeutics Inc Stock (WINT) Company Profile
Name
Windtree Therapeutics Inc
Sector
Industry
Phone
(215) 488-9300
Address
2600 KELLY ROAD, WARRINGTON, PA
Windtree Therapeutics Inc Stock (WINT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-26-20 | Initiated | Ladenburg Thalmann | Buy |
Windtree Therapeutics Inc Stock (WINT) Latest News
Windtree reports positive heart failure drug study results - Investing.com
Windtree Announces Positive Phase 2b Topline Clinical - GlobeNewswire
Windtree Therapeutics Announces Promising Results for Heart Failure Drug - MSN
Windtree Therapeutics Announces Key Investor Day for Groundbreaking Heart Treatment - MSN
Windtree Therapeutics Announces Key Investor Day for Groundbreaking Heart Treatment - MyChesCo
Windtree Therapeutics Announces Virtual Investor Day Presentation on October 1 at 3pm ET - GlobeNewswire
Windtree Therapeutics Announces Virtual Investor Day Presentation on October 1 at 3pm ET - StockTitan
Windtree Therapeutics Announces Promising Results for Heart Failure Drug - MyChesCo
Financial Metrics Unveiled: Windtree Therapeutics Inc (WINT)’s Key Ratios in the Spotlight - The Dwinnex
Windtree Therapeutics Inc (WINT) Stock: A Year of Stock Market Ups and Downs - The InvestChronicle
Short Interest in Windtree Therapeutics, Inc. (NASDAQ:WINT) Declines By 65.9% - Defense World
WINT’s price-to-sales ratio: Is it a good investment opportunity? - US Post News
Windtree Therapeutics Heart Failure Drug Candidate Improves Systolic Blood Pressure - AOL
Windtree stock slides amid Phase 2b data for istaroxime for cardiogenic shock - MSN
Windtree Therapeutics Heart Failure Drug Candidate Improves Systolic Blood Pressure - Yahoo Finance
Windtree reports positive Phase 2b results for heart failure drug - Investing.com
Windtree Announces Positive Topline Results from Its Phase - GlobeNewswire
Windtree Announces Positive Topline Results from Its Phase 2b SEISMiC Extension Study of Istaroxime in Early Cardiogenic Shock - StockTitan
Windtree Therapeutics secures stockholder approvals in key proposals - Investing.com India
Windtree Therapeutics secures stockholder approvals in key proposals - Investing.com
Windtree Therapeutics secures stockholder approvals in key proposals By Investing.com - Investing.com UK
Westwood Holdings Group Inc. Reduces Holdings in Rivian Automotive, Inc. (NASDAQ:RIVN) - Defense World
Despite delivering investors losses of 81% over the past 3 years, Weibo (NASDAQ:WB) has been growing its earnings - Simply Wall St
Intuit director Burton Eve B sells nearly $1.94m in company stock - Investing.com
Rivian Automotive (NASDAQ:RIVN) Shares Up 2% - MarketBeat
Weibo (NASDAQ:WB) Shares Up 3.9% - Defense World
WINTON GROUP Ltd Takes $409,000 Position in BWX Technologies, Inc. (NYSE:BWXT) - Defense World
WINTON GROUP Ltd Takes Position in WEBTOON Entertainment Inc. (NASDAQ:WBTN) - Defense World
Windtree Therapeutics (NASDAQ:WINT) Shares Up 3.7% - Defense World
Rivian Automotive Inc [RIVN] Investment Appeal on the Rise - Knox Daily
Is Windtree Therapeutics Inc’s (NASDAQ:WINT) Stock On The Decline? - Stocks Register
Rivian Automotive, Inc. (NASDAQ:RIVN) Shares Sold by State of New Jersey Common Pension Fund D - Defense World
Quest Partners LLC Has $90,000 Holdings in Rivian Automotive, Inc. (NASDAQ:RIVN) - Defense World
Private Advisor Group LLC Raises Stock Holdings in Rivian Automotive, Inc. (NASDAQ:RIVN) - Defense World
Rivian Automotive, Inc. (NASDAQ:RIVN) Shares Purchased by Forsta AP Fonden - Defense World
Understanding WINT stock ratios for better investment decisions - US Post News
WINT’s Market Quandary: Decoding the Ups and Downs of 2023 - The InvestChronicle
In the Green: Windtree Therapeutics Inc (WINT) Closes at 3.45, Up/Down 23.21 from Previous Day - The Dwinnex
Windtree Therapeutics Advances Heart Failure Treatment with SEISMiC Extension Study Completion - MSN
Windtree Therapeutics Advances Heart Failure Treatment with SEISMiC Extension Study Completion - MyChesCo
Take off with Windtree Therapeutics Inc (WINT): Get ready for trading - SETE News
WINT stock touches 52-week low at $2.8 amid sharp annual decline - Investing.com
WINT stock touches 52-week low at $2.8 amid sharp annual decline - Investing.com Canada
Market Insights: Windtree Therapeutics Inc (WINT)’s Notable Gain of 4.08, Closing at 3.32 - The Dwinnex
Windtree Therapeutics Inc’s: Contrasting Stock Performances in a Volatile Market - The InvestChronicle
What's Going On With Windtree Therapeutics Stock Wednesday? - Benzinga
Windtree (WINT) Stock Climbs In Pre-Market Trading After Major Update - Stocks Telegraph
Windtree Completes Enrollment of Phase 2b Study of Istaroxime in Early Cardiogenic Shock - GlobeNewswire
Windtree Completes Enrollment of Phase 2b Study of Istaroxime in Early Cardiogenic Shock - StockTitan
When the Price of (WINT) Talks, People Listen - Stock Traders Daily
Windtree Therapeutics, Inc. (NASDAQ:WINT) Short Interest Down 56.8% in August - Defense World
Windtree Therapeutics Inc Stock (WINT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):